PMID- 14565663
OWN - NLM
STAT- MEDLINE
DCOM- 20040323
LR  - 20190116
IS  - 1042-8194 (Print)
IS  - 1026-8022 (Linking)
VI  - 44
IP  - 9
DP  - 2003 Sep
TI  - Abundant expression of spliced HDM2 in Hodgkin lymphoma cells does not interfere 
      with p14(ARF) and p53 binding.
PG  - 1587-96
AB  - Recently, comparative genomic hybridization (CGH)- and fluorescence in situ 
      hybridization (FISH)-analyses of native Hodgkin and Reed-Sternberg (H&RS) cells 
      extracted from Hodgkin lymphoma (HL) revealed a recurrent amplification of the 
      HDM2 locus on chromosome 12. HDM2 is known to target, inactivate and to degrade 
      p53. Wild type (wt) p53 protein is detected in high levels in HL. Simultaneously, 
      stabilized wt p53 and spliced hdm2 transcripts have been observed in different 
      tumors. Therefore, we examined the expression and structure of HDM2 in HL cell 
      lines and possible effects on components of the p53 pathway. DNA integrity and 
      induction potential of p53 was verified by DNA sequencing and detection of 
      potential effector proteins (p21(WAF/CIP), HDM2) using immunofluorescence, 
      respectively. All HL cell lines show an overexpression of HDM2 protein. 
      Furthermore, several different spliced hdm2 transcripts (mdm-sv) including five 
      new variants lacking a functional p53 binding site were characterized. If 
      expressed, corresponding proteins were shown to be not restricted to the nucleus. 
      Co-localization of the potential binding partners HDM2/p14(ARF) and HDM2/p53 was 
      found in HL cell lines. We suggest that HDM2-sv have no significant disturbing 
      influence on the interaction of these proteins.
FAU - Sturzenhofecker, Benjamin
AU  - Sturzenhofecker B
AD  - Department of Haematologie and Oncology, Georg August University, Goettingen 
      37075, Germany. b.stuerzen@med.uni-goettingen.de
FAU - Schlott, Thilo
AU  - Schlott T
FAU - Quentin, Thomas
AU  - Quentin T
FAU - Kube, Dieter
AU  - Kube D
FAU - Jung, Wolfram
AU  - Jung W
FAU - Trumper, Lorenz
AU  - Trumper L
LA  - eng
PT  - Comparative Study
PT  - Journal Article
PT  - Research Support, Non-U.S. Gov't
PL  - United States
TA  - Leuk Lymphoma
JT  - Leukemia & lymphoma
JID - 9007422
RN  - 0 (CDKN1A protein, human)
RN  - 0 (Cyclin-Dependent Kinase Inhibitor p21)
RN  - 0 (Cyclins)
RN  - 0 (Neoplasm Proteins)
RN  - 0 (Nuclear Proteins)
RN  - 0 (Proto-Oncogene Proteins)
RN  - 0 (RNA, Messenger)
RN  - 0 (RNA, Neoplasm)
RN  - 0 (Tumor Suppressor Protein p14ARF)
RN  - 0 (Tumor Suppressor Protein p53)
RN  - EC 2.3.2.27 (MDM2 protein, human)
RN  - EC 2.3.2.27 (Proto-Oncogene Proteins c-mdm2)
SB  - IM
MH  - *Alternative Splicing
MH  - Binding Sites
MH  - Cell Line, Tumor/metabolism
MH  - Cell Nucleus/metabolism
MH  - Cyclin-Dependent Kinase Inhibitor p21
MH  - Cyclins/biosynthesis/genetics
MH  - DNA Methylation
MH  - Gene Expression Regulation, Neoplastic
MH  - Hodgkin Disease/*genetics/metabolism/pathology
MH  - Humans
MH  - In Situ Hybridization, Fluorescence
MH  - Neoplasm Proteins/chemistry/genetics/*metabolism/pharmacology
MH  - *Nuclear Proteins
MH  - Polymerase Chain Reaction
MH  - Protein Binding
MH  - Proto-Oncogene Proteins/chemistry/genetics/*metabolism/pharmacology
MH  - Proto-Oncogene Proteins c-mdm2
MH  - RNA, Messenger/metabolism
MH  - RNA, Neoplasm/metabolism
MH  - Reed-Sternberg Cells/metabolism
MH  - Sequence Deletion
MH  - Tumor Suppressor Protein p14ARF/antagonists & inhibitors/*metabolism
MH  - Tumor Suppressor Protein p53/antagonists & inhibitors/*metabolism
EDAT- 2003/10/21 05:00
MHDA- 2004/03/24 05:00
CRDT- 2003/10/21 05:00
PHST- 2003/10/21 05:00 [pubmed]
PHST- 2004/03/24 05:00 [medline]
PHST- 2003/10/21 05:00 [entrez]
AID - 10.3109/10428190309178783 [doi]
PST - ppublish
SO  - Leuk Lymphoma. 2003 Sep;44(9):1587-96. doi: 10.3109/10428190309178783.